Recently, Beijing tricision Biotech Co., Ltd. (tricision) and China Resources Biopharmaceutical Co., Ltd. (China Resources Biopharmaceutical) signed a strategic cooperation agreement to jointly develop an mRNA vaccine for the treatment of glioblastoma multiforme (GBM). This partnership will accelerate tricision's clinical research and commercialization process, while further advancing China Resources Biopharmaceutical's portfolio positioning in central nervous system tumor therapeutics and clinical strategy coordination, contributing to the integrated development of the biopharmaceutical industry.

GBM is the most common primary malignant tumor of the central nervous system, with extremely high malignancy earning it the grim label of "the new king of cancers." Currently, clinical treatment outcomes for GBM are limited, with low patient survival rates and a median overall survival of only 13.5 months—making it one of the most challenging conditions in neurosurgery, with an urgent need for more effective solutions.

It is reported that tricision's mRNA-DC vaccine for primary GBM—Survivin-Targeting DC Cell Injection—received Clinical Trial Permission (CTP) from the Center for Drug Evaluation (CDE) on January 10, 2023, becoming the first mRNA-DC therapeutic cancer vaccine in China to receive clinical trial approval. Earlier exploratory clinical studies showed that combining this mRNA-DC vaccine with anti-PD-1 and Poly I:C resulted in progression-free survival exceeding 5 years in patients with Grade IV GBM.

China Resources Biopharmaceutical has deep industrial foundations, rich clinical resources, and strong market capabilities. With a forward-looking strategy in mRNA nucleic acid vaccines, the company is diversifying its pipeline through the introduction of novel mRNA technology platforms, providing combination immunotherapy solutions for major clinical needs including malignant tumors, benefiting more patients and supporting the Healthy China strategy.

Mr. Liu Dong, CEO of tricision, stated: "We greatly appreciate the strong recognition from China Resources Biopharmaceutical. As a leading BioPharma with global influence, China Resources Biopharmaceutical possesses extensive R&D, manufacturing, and marketing resources in biologics. mRNA technology is advancing rapidly in cancer, infectious diseases, and immunological disorders. tricision's platform technologies and production systems are of great significance for meeting China's innovation needs, production capacity demands, and clinical requirements in mRNA nucleic acid drugs and Cell and Gene Therapy (CGT)—ensuring accessible supply and advancing industrial chain development. As one of the earliest Chinese companies to apply mRNA technology in solid tumor clinical research, we have deep understanding and clear strategies in the scientific foundation, technological innovation, and product development of mRNA. We hope that through this strategic partnership with China Resources Biopharmaceutical, we can further iterate and upgrade our technology platforms, empower industrial economic development and global commercial positioning, and accelerate the manufacturing translation and clinical application of mRNA drugs to advance the industry."

Mr. Yin Huijun, CEO of China Resources Biopharmaceutical, commented: "We are very optimistic about the biotechnological innovation led by mRNA technology. As a new frontier in disease treatment, mRNA therapy is one of the most promising directions in biopharmaceutical development. tricision has a world-class scientific R&D team and an exceptionally innovative R&D platform. Its core 'One Body, Two Wings' platform technologies cover the key aspects of mRNA drug development, organically combining capabilities to truly achieve platformization. As the innovative biologics platform of the China Resources Pharmaceutical Group, we are committed to strengthening our full-chain biologics capabilities—from R&D and manufacturing to sales—continuously advancing modern production and high-level R&D to meet unmet clinical needs. Through a combination of independent R&D and external partnerships, we are enriching our product pipeline, driving sustained technological transformation, and gradually expanding our biopharmaceutical platform. Through this strategic partnership with tricision, we aim to advance mRNA development for both parties."

About tricision

As one of the earliest biopharmaceutical enterprises in China to engage in cellular immunotherapy and mRNA nucleic acid drug technological innovation and product R&D, tricision upholds the mission of "transforming cancer into a chronic, manageable disease," adhering to the development philosophy of "people-oriented, technology for good, innovation-driven, and future-leading." The Company is committed to promoting innovative R&D, manufacturing translation, and clinical application of mRNA and other nucleic acid drugs, providing effective solutions for the prevention and treatment of malignant tumors, infectious diseases, autoimmune disorders, and genetic diseases.

tricision possesses three major technology platforms—"One Body" (nucleic acid technology) and "Two Wings" (LNP delivery and DC delivery) —with triVAC and C2 as core patents. The Company has filed 46 invention patents related to mRNA technologies, of which 22 have been granted. It has established an integrated in-house R&D and production system and exceptional Chemistry, Manufacturing, and Controls (CMC) translation capabilities, breaking through key industrial technology bottlenecks and achieving in-house production of raw material enzymes, plasmids, mRNA, and LNP. The Company supports R&D of multiple products across two pipelines: therapeutic cancer vaccines and prophylactic vaccines for infectious diseases.

About China Resources Biopharmaceutical

China Resources Biopharmaceutical is the innovative biologics platform of the China Resources Pharmaceutical Group. The Company is innovation-driven and R&D-focused, with deep positioning across the full biologics industrial chain. Its independent innovation capabilities span the entire drug development lifecycle—from molecular discovery, process development, translational medicine, and clinical development to commercial manufacturing. Its business encompasses biologics R&D, manufacturing, and sales. With proprietary core technologies, the Company is committed to building original technology platforms for combination innovation and aims to become a source of original technologies in the biologics field. With early-stage innovation R&D platforms, CMC process development and quality control, flexible pilot-scale facilities, and commercial manufacturing bases, it is one of the few biologics companies in China with a full-chain development platform. It currently has 3 marketed biologics and 20+ biologics in the R&D pipeline, including one in Phase III, two in Phase II, and one in Phase I. Its R&D team comprises nearly 10 overseas and nationally recognized high-level talents, with over 85% holding master's or doctoral degrees, and the Company has undertaken multiple national "Major New Drug Development" science and technology special projects.